113 related articles for article (PubMed ID: 23138529)
21. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
[TBL] [Abstract][Full Text] [Related]
22. Absence of ethnic difference on single-dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects.
Sachar M; Park CH; Pesco-Koplowitz L; Koplowitz B; McGinn A
Fundam Clin Pharmacol; 2021 Apr; 35(2):485-495. PubMed ID: 33098705
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats.
Minematsu T; Sonoda T; Hashimoto T; Iwai M; Oppeneer T; Felder L; Shirai N; Miyashita A; Usui T
Biopharm Drug Dispos; 2012 Apr; 33(3):160-9. PubMed ID: 22374735
[TBL] [Abstract][Full Text] [Related]
24. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.
Hijazi Y; Klinger M; Kratzer A; Wu B; Baeuerle PA; Kufer P; Wolf A; Nagorsen D; Zhu M
Curr Clin Pharmacol; 2018; 13(1):55-64. PubMed ID: 29773068
[TBL] [Abstract][Full Text] [Related]
27. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.
Uenaka K; Nakano M; Willis BA; Friedrich S; Ferguson-Sells L; Dean RA; Ieiri I; Siemers ER
Clin Neuropharmacol; 2012; 35(1):25-9. PubMed ID: 22134132
[TBL] [Abstract][Full Text] [Related]
28. Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Wang D; Braiteh F; Lee JJ; Denlinger CS; Shepard DR; Chaudhary A; Lin Y; Gao L; Asakiewicz C; Nasroulah F; LoRusso P
Cancer Chemother Pharmacol; 2016 Oct; 78(4):727-33. PubMed ID: 27507037
[TBL] [Abstract][Full Text] [Related]
29. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.
Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2014 Apr; 92():144-8. PubMed ID: 24518133
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
[TBL] [Abstract][Full Text] [Related]
31. Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Hatake K; Chou T; Doi T; Terui Y; Kato H; Hirose T; Seo S; Pourdehnad M; Ogaki Y; Fujimoto H; Hagner PR; Yamamoto K
Cancer Sci; 2021 Jan; 112(1):331-338. PubMed ID: 33075165
[TBL] [Abstract][Full Text] [Related]
32. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Doi T; Fujiwara Y; Shitara K; Shimizu T; Yonemori K; Matsubara N; Ohno I; Kogawa T; Naito Y; Leopold L; Munteanu M; Yatsuzuka N; Han SR; Samkari A; Yamamoto N
Invest New Drugs; 2021 Feb; 39(1):152-162. PubMed ID: 32564277
[TBL] [Abstract][Full Text] [Related]
33. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects.
Morrison M; Palermo G; Schmitt C
Eur J Clin Pharmacol; 2015 Nov; 71(11):1365-74. PubMed ID: 26363899
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
[TBL] [Abstract][Full Text] [Related]
35. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.
Aiudi A; Miller B; Krishna G; Adedoyin A; Xiao A
Fundam Clin Pharmacol; 2016 Dec; 30(6):625-633. PubMed ID: 27473285
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Honda K; Tamura Y; Wakui H; Sasaki T; Yusa W; Fujino K; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1153-61. PubMed ID: 26530955
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
[TBL] [Abstract][Full Text] [Related]
40. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
